Unlike AFP and PIVKA-II, ESPL1 levels progressively increased across the CHB, LC, and HBV-HCC groups with substantial changes, specifically from 224.6 ng/L to 285.8 ng/L to 440.4 ng/L. This evidence concerns the gene AFP and hepatocellular carcinoma.